Brill Research

Investment theses backed by deep fundamental & technical analysis

[Brill Research @BrillResearch]

@Uzwzp63636 @ConstantinBell Interesting, even considering their massive moat of over 400M accounts?

[Brill Research @BrillResearch]

$PYPL at this point, what's more likely?
1. PayPal gets acquired
2. PayPal buying back every single share outstanding with its massive FCF generation
3. PayPal's FCF deteriorating to the point where the company goes bankrupt

[Brill Research @BrillResearch]

@ConstantinBell seems reasonable.

[Brill Research @BrillResearch]

$BNTX And a small reminder: even higher interest rates are actually a tailwind, given that BNTX generates $500M+ in annual interest income.
In my view, this is already a $100+ stock. The market is massively underappreciating the value of the pipeline and balance sheet.

[Brill Research @BrillResearch]

$BNTX is, in my opinion, significantly undervalued.
- 20+ ongoing Phase II & III studies
- A COVID business still generating a ~$2B annual revenue run rate
- Over $18B in cash and equivalents

[Brill Research @BrillResearch]

$BNTX is, in my opinion, significantly undervalued.
- 20+ ongoing Phase II & III studies
- A COVID business still generating a ~$2B annual revenue run rate
- Over $18B in cash and equivalents

[Brill Research @BrillResearch]

$BNTX sitting on ~$19.7B in cash (current FX) with promising clinical progress for pumitamig. Still a waiting game until oncology launches materialize. A $1 billion SRP feels premature — better to deploy that capital into BD or keep it in yield-generating securities to fund R&D.

[Brill Research @BrillResearch]

$APPS If management continues to deliver and the market rerates the stock to around 20x EV/EBITDA, I believe prices above $20—and potentially into the $30 range—could be achievable over the medium term.
As always, it all comes down to execution.

[Brill Research @BrillResearch]

$APPS is holding up nicely above $10. A consolidation around the $9–10 range would actually be healthy and could set the stage for the next leg higher.
The key will be continued fundamental execution: sustained revenue growth, improving profitability, and ongoing debt reduction.

[Brill Research @BrillResearch]

$APPS is shooting out of the gate again today, looking ready to break through the $10 area. There are still over 10M shares sold short, with weekly and monthly charts curling higher on strong volume.
I remain long.

[Brill Research @BrillResearch]

@alc2022 Congrats! Very nice call.

[Brill Research @BrillResearch]

$APPS The break above $8 was a significant technical development on the monthly chart, as the prior bounce into that level has now been decisively taken out.

[Brill Research @BrillResearch]

$APPS is shooting out of the gate again today, looking ready to break through the $10 area. There are still over 10M shares sold short, with weekly and monthly charts curling higher on strong volume.
I remain long.

[Brill Research @BrillResearch]

$APPS has seen multiple spikes toward the $10 level over the past year, but this move feels different. The stock surged following solid earnings, and historically, similar rallies were sold off heavily in the following weeks. This time, however, it is holding up remarkably well.

[Brill Research @BrillResearch]

@Maymoonsoon The stock is still up over 100% from recent lows of $13/share.

[Brill Research @BrillResearch]

$HIMS is now trading in a fresh weekly uptrend, with more than 30% of the float currently sold short. If the bullish momentum continues, the elevated short interest could add further fuel to the move.

[Brill Research @BrillResearch]

$APPS It increasingly looks like a more structural reversal, supported by improving growth trends and a return to profitability.

[Brill Research @BrillResearch]

$APPS has seen multiple spikes toward the $10 level over the past year, but this move feels different. The stock surged following solid earnings, and historically, similar rallies were sold off heavily in the following weeks. This time, however, it is holding up remarkably well.

[Brill Research @BrillResearch]

$APPS continues to rally, now approaching $10/share.
As mentioned previously, the latest earnings report showed encouraging progress and a clear path toward continued revenue growth, profitability expansion, and debt reduction.

[Brill Research @BrillResearch]

$APPS to further reduce debt and lower interest expense.
Still holding and looking forward to what comes next.

[Brill Research @BrillResearch]

$APPS continues to rally, now approaching $10/share.
As mentioned previously, the latest earnings report showed encouraging progress and a clear path toward continued revenue growth, profitability expansion, and debt reduction.

[Brill Research @BrillResearch]

$APPS showing a major weekly breakout here and curling up very nicely on extraordinary volume following quarterly results.
The company returned to double-digit revenue and EBITDA growth while also deleveraging with a $50M debt paydown.

[Brill Research @BrillResearch]

$APPS While the recent move may have been somewhat exaggerated in the short term, it increasingly looks like a genuine trend reversal. It would also be reasonable for the company to take advantage of this strength by issuing additional shares through its ATM program

[Brill Research @BrillResearch]

$APPS The biggest overhang remains the ~$350M debt load, but the recent repayment activity is encouraging, especially as the business and profitability continue to reaccelerate.
Still trading at under 10x NTM EV/EBITDA.

[Brill Research @BrillResearch]

$APPS showing a major weekly breakout here and curling up very nicely on extraordinary volume following quarterly results.
The company returned to double-digit revenue and EBITDA growth while also deleveraging with a $50M debt paydown.

[Brill Research @BrillResearch]

That would imply roughly a $20B EV, or around $80–90/share depending on future debt levels and dilution/buybacks.
That implies roughly a ~30% share price CAGR from today’s ~$25 levels through 2030, an r/r profile I’m willing to take. $HIMS

[Brill Research @BrillResearch]

$HIMS reported a weak Q1, but still raised FY26 revenue and EBITDA guidance while reiterating its 2030 ambition of $1.3B+ EBITDA. At a conservative and reasonable 15x EV/EBITDA multiple (considering continued double-digit growth across revenue, EPS, and EBITDA).